RPAM
MIRM icon

Rhenman & Partners Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Buy
139,205
+46,600
+50% +$4.68M 1.54% 21
2026
Q1 		$8.55M Sell
92,605
-13,650
-13% -$1.28M 1.06% 38
2025
Q4 		$8.39M Buy
106,255
+50,000
+89% +$3.59M 0.78% 51
2025
Q3 		$4.12M Sell
56,255
-9,500
-14% -$604K 0.46% 62
2025
Q2 		$3.35M Sell
65,755
-8,000
-11% -$356K 0.42% 62
2025
Q1 		$3.32M Hold
73,755
– – 0.38% 56
2024
Q4 		$3.05M Sell
73,755
-31,245
-30% -$1.3M 0.31% 69
2024
Q3 		$4.09M Sell
105,000
-29,250
-22% -$1.17M 0.33% 70
2024
Q2 		$4.59M Buy
134,250
+42,000
+46% +$1.1M 0.44% 57
2024
Q1 		$2.32M Buy
+92,250
New +$2.54M 0.22% 72

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rhenman & Partners Asset Management's MIRM Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Mirum Pharmaceuticals (MIRM) stake by 50% in Q2 2026, buying an estimated $4.68M and bringing the position to 139,205 shares worth $16.3M. The position accounts for 1.54% of the portfolio, ranked #21.

Rhenman & Partners Asset Management first reported a position in MIRM in Q1 2024 and has held it in 10 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Rhenman & Partners Asset Management held 139,205 shares of Mirum Pharmaceuticals worth $16.3M as of Q2 2026.
  • Rhenman & Partners Asset Management bought 46,600 Mirum Pharmaceuticals shares in Q2 2026, an estimated $4.68M.
  • Mirum Pharmaceuticals made up 1.54% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #21 holding.
  • Rhenman & Partners Asset Management first reported a position in Mirum Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.